Form 8-K - Current report:
SEC Accession No. 0001193125-22-260620
Filing Date
2022-10-11
Accepted
2022-10-11 16:13:59
Documents
13
Period of Report
2022-10-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d293559d8k.htm   iXBRL 8-K 26482
2 EX-10.1 d293559dex101.htm EX-10.1 8078
  Complete submission text file 0001193125-22-260620.txt   154141

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rcus-20221011.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rcus-20221011_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rcus-20221011_pre.xml EX-101.PRE 10808
7 EXTRACTED XBRL INSTANCE DOCUMENT d293559d8k_htm.xml XML 3226
Mailing Address 3928 POINT EDEN WAY HAYWARD CA 94545
Business Address 3928 POINT EDEN WAY HAYWARD CA 94545 (510) 694-6200
Arcus Biosciences, Inc. (Filer) CIK: 0001724521 (see all company filings)

EIN.: 473898435 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38419 | Film No.: 221304214
SIC: 2834 Pharmaceutical Preparations